CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Mitsiades
Constantine S
CS
Dept. of Medical Oncology, Dana-Farber Cancer Institute, Dept. of Medicine, Harvard Medical School, Boston, Mass., USA. constantine_mitsiades@dfci.harvard.edu.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics*; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology*; D007167:Immunotherapy; D017404:In Situ Hybridization, Fluorescence; D007952:Leukemia, Plasma Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D010265:Paraproteinemias / Q000235:genetics / Q000276:immunology / Q000628:therapy; D047368:Tumor Burden / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C112697:CD44v6 antigen; D006023:Glycoproteins; D018960:Hyaluronan Receptors